Clinical trials: H Pylori Eradication
H. Pylori Infection
H. Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy
The rate of H. pylori resistance to antimicrobial agents including clarithromycin (CAM) has increased worldwide. Eradication failure using triple therapy is strongly associated with CAM-resistant H. pylori.
- Trial name
- NCT05002595
- Testing
- H. pylori eradication
- Where
- South Korea
- Volunteers
- 270 people
- Sponsor
- Soonchunhyang University Hospital
Helicobacter Pylori Infection
Comparing the Efficacy of 10-day Reverse Hybrid Therapy and 10-day Triple Therapy Plus Bismuth Therapy.
Reverse hybrid therapy achieves a higher eradication rate than triple therapy plus bismuth therapy remains unanswered.
- Trial name
- NCT04566211
- Testing
- (panto+amox+clar+metr)+(panto+amox), pantoprazole+bismuth+amox+clar
- Where
- Taiwan
- Volunteers
- 440 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
Compare efficacy and safety of 10-day triple therapy (rabeprazole, clarithromycin and amoxicillin) plus N-acetylcystein versus 10-day concomitant therapy (rabeprazole, clarithromycin, amoxicillin and metronidazole) for…
- Trial name
- NCT01572597
- Testing
- 10RAC+acetylcystein, 10RAC+metronidazole
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Helicobacter Pylori Infection
Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication
Vonoprazan and high-dose amoxicillin dual therapy was used as a control group to evaluate the clinical efficiency and safety of Banxiaxiexin decoction combined with vonoprazan and high-dose amoxicillin dual therapy in the…
- Trial name
- NCT06340724
- Testing
- Vonoprazan, Amoxicillin, Banxiaxiexin decoction
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
HELICOBACTER PYLORI INFECTIONS
Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori）
This study is designed to evaluate two different tegoprazan-based dual therapy regimens for the treatment of Helicobacter pylori (H. pylori) infection.
- Trial name
- FAST-HP (NCT07242443)
- Testing
- Tegoprazan 50 mg, Amoxicillin 1 g TID, Amoxicillin 1.5 g BID
- Where
- China
- Volunteers
- 240 people
- Sponsor
- First People's Hospital of Hangzhou
Helicobacter Pylori Infection
Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole
In Mexico, quadruple therapy is used to treat Helicobacter pylori (H.P.) at the expense of greater adverse effects, costs, and lower adherence to treatment.
- Trial name
- NCT06318104
- Testing
- Tegoprazan, Esomeprazole 40mg
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Hospital General de México Dr. Eduardo Liceaga
H. Pylori Infection, Gastric Ulcer
Pepsinogens as the Early Marker of H. Pylori Eradication
Helicobacter pylori (H. pylori) eradication increases the serum pepsinogen (PG) I/PG II ratio and the percentage change in PG I/PG II ratios was found to be a useful marker of H. pylori eradication (e.g., the PG method).
- Conditions
- H. Pylori Infection, Gastric Ulcer, Duodnal Ulcer
- Trial name
- NCT00197457
- Testing
- serum pepsinogen, urea breath test
- Where
- Japan
- Sponsor
- Hamamatsu University
Helicobacter
7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori
Helicobacter pylori infection is a prevalent global gastrointestinal condition linked to chronic gastritis, peptic ulcer disease, and gastric cancer. Potent and sustained acid suppression improves eradication efficacy.
- Trial name
- NCT07352098
- Testing
- 7-day high-dose vonoprazan-amoxicillin dual therapy group, 14-day vonoprazan-amoxicillin dual therapy group
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Yueyue Li
Helicobacter
Sequential Therapy Versus Quadruple Therapy in H. Pylori Eradication
The investigators aimed to 1. compare the eradication rates and long term re-infection rates of sequential therapy for 14 days versus bismuth quadruple therapy for 10 days in the first line and second line treatment 2.
- Trial name
- NCT03156855
- Testing
- 14-day sequential therapy, Bismuth quadruple therapy
- Where
- 7 sites in Taiwan
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Helicobacter Pylori Infection
VA Dual Sequential Therapy
Sequential therapy for Hp was first introduced by Zullo et al. in 2000 and consists of two phases: the first phase involves proton pump inhibitors with one antibiotic, and the second phase involves proton pump inhibitors with two…
- Trial name
- JSHERO3 (NCT06929962)
- Testing
- Vonoprazan and Amoxicillin for the first 7 days, Vonoprazan and Amoxicillin for the first 5 days, Vonoprazan and Amoxicillin for the second 7 days
- Where
- China
- Volunteers
- 600 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Functional Dyspepsia, Helicobacter Pylori Infection
Clinical Study to Evaluate the Efficacy and the Safety of Eradication Therapy for Helicobacter Pylori in Functional Dyspepsia
The role of Helicobacter pylori infection in functional dyspepsia remains controversial. Several randomized controlled trials in western countries have shown no significant advantage over placebo.
- Trial name
- NCT00990405
- Testing
- Lansoprzole+Amoxicillin+Clarithromycin
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Korean College of Helicobacter and Upper Gastrointestinal Research
Helicobacter Pylori Infection, Helicobacter Gastritis
Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication
The hypothesis and plan of the current study are: 1. One induction phase of high dose PPI before eradication will increase intragastric pH and induce H. pylori into an active replicative status.
- Conditions
- Helicobacter Pylori Infection, Helicobacter Gastritis, Helicobacter-Associated Pyloric Ulcer
- Trial name
- NCT03802318
- Testing
- Rabeprazole
- Where
- Taiwan
- Volunteers
- 530 people
- Sponsor
- Chang Gung Memorial Hospital
H. Pylori Infection
Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
The purpose of this study is to confirm the efficacy of triple therapy with TAK-438, Amoxicillin and Clarithromycin, twice daily (BID) by demonstrating its non-inferiority to triple therapy with Lansoprazole, Amoxicillin and…
- Trial name
- NCT01505127
- Testing
- TAK-438, Lansoprazole, Amoxicillin
- Where
- 35 sites in Japan
- Volunteers
- 650 people
- Sponsor
- Takeda
Helicobacter Pylori Infection
Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication
Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various bismuth-containging quadruple regimens and identify…
- Trial name
- RETRO-HP (NCT07167511)
- Testing
- This study is a retrospective study, and all data have been collected in advance with no active intervention required.
- Where
- China
- Volunteers
- 1,730 people
- Sponsor
- Yueyue Li
Helicobacter Pylori Infection
A Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.
- Trial name
- NCT05493644
- Testing
- Remedial treatment within 3 months, Remedial treatment within 3 to 6 months, Remedial treatment within 6 to 12 months
- Volunteers
- 660 people
- Sponsor
- Shandong University
Duodenal Ulcer
Helicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers
The Study purpose is to evaluate Helicobacter pylori susceptibility to Clarithromycin and to estimate eradication and healing rates of duodenal ulcer routine eradication therapy at the end of treatment and 52 weeks from the…
- Trial name
- NCT01199536
- Where
- Russia
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Peptic Ulcer, Helicobacter Pylori Infection
Clarithromycin Resistant Tailored Therapy
1. Back ground Antibiotics resistance of Helicobacter pylori, especially to clarithromycin is one of the main causes of failure of eradication.
- Trial name
- NCT01453036
- Testing
- 23S rRNA point mutation test of Helicobacter pylori, UBT test & Gastroenterology with biopsy c silver stain
- Where
- South Korea
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Jin Il Kim
Helicobacter Infection
The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection
To compare the eradication success rate between 10-days sequential therapy and 7-days tailored therapy based on H. pylori culture and antimicrobial susceptibility testing.
- Trial name
- NCT02373280
- Testing
- 10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole), 7 day tailored PPI triple therapy (clarithromycin-containing triple therapy), 7 day moxifloxacin based triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Helicobacter Pylori Infection
The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection
The researchers collect patients who accepted eradication program of the helicobacter pylori but failed to eradicate helicobacter pylor from the outpatient clinic.
- Trial name
- NCT05620589
- Testing
- Amoxicillin + Tetracycline + Bismuth + Esomeprazole, Amoxicillin + Tetracycline + Bismuth + Vonoprazan, Amoxicillin + Tetracycline + Bismuth + Tegoprazan
- Where
- China
- Volunteers
- 626 people
- Sponsor
- Shandong University
Helicobacter Pylori Infection
Vonoprazan Evaluation Compared to Standard Triple Therapy in Helicobacter Pylori eRadication
Helicobacter pylori (H Pylori) infection is associated with functional dyspepsia, peptic ulcer disease, atrophy and gastric cancer. The bacterium has been classified as grade I carcinogen by the WHO in 1994(1).
- Trial name
- NCT06959368
- Testing
- Vonoprazan 20mg, Esomeprazole 40 mg, Amoxicillin 1 g, Clarithromycin 500 mg
- Where
- India
- Volunteers
- 484 people
- Sponsor
- Asian Institute of Gastroenterology, India